Q2:2021 Earnings Update August 2021 Forward Looking Statement 2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current an ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Bryan Giraudo - Chief Financial Officer Faheem Hasnain - Chairman, Co-Founder and Chief Executive Officer Richard Aranda - Chief Medical Officer Conference Call Participants Joseph Schwartz - SVB Leerink Olivia Brayer - Bank of America Merrill Lynch Patrick Trucchio - H.C. Wainwright Emma Nealon - Cantor Fitzgerald Operator Good day and thank you for standing by. Welcome to the Gossamer Bio Q2 Ea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to_________. Commission File Number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified in its charter). _________________________ | Delaware | 47-5461709 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | WASHINGTON, D.C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to_________. Commission File Number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant ...

go frame bio 1 Corporate Presentation February 2021 Forward Looking Statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Q4 2020 Earnings Conference Call February 25, 2021 8:30 AM ET Company Participants Bryan Giraudo - CFO Faheem Hasnain - Co-Founder, CEO, & Chairman Richard Aranda - SVP, Clinical Development Conference Call Participants Unidentified Analyst - Carter Gould - Barclays Bank Emma Nealon - Cantor Fitzgerald & Co. Olivia Brayer - Bank of America Securities Patrick Trucchio - H.C. Wainwright & Co Unidentified Analyst - SMBC Operator Ladies and gentlemen, thank you for standing ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________________________________________________ FORM 10-K __________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 _____ ...

go frame bio 1 Corporate Presentation November 2020 Forward Looking Statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results ...

Start Time: 16:30 January 1, 0000 5:30 PM ET Gossamer Bio, Inc. (NASDAQ:GOSS) Q3 2020 Earnings Conference Call November 10, 2020, 16:30 PM ET Company Participants Sheila Gujrathi - Co-Founder and CEO Bryan Giraudo - CFO Luisa Salter-Cid - Chief Scientific Officer Richard Aranda - SVP, Head of Clinical Development Conference Call Participants Tyler Van Buren - Piper Sandler Joseph Schwartz - SVB Leerink Geoff Meacham - Bank of America Merrill Lynch Josh Schimmer - Evercore ISI Carter Gould - Barclays Emma Ne ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ (Exact name of Registrant as specified in its charter). _________________________ | Delaware | | | 47-5461709 | | --- | --- | --- | --- | | (State or other jurisdiction of | | | (I.R.S. Employer | | incorporation or organization) | | | Identification No.) | | 3013 Science Park Road | San Diego | California | 92121 | | (Address of principal executive offices) ...